Jessina Graham (@PotsyNP) header
Jessina Graham (@PotsyNP) profile picture

C-NP, FNP, Zoologist, EDS specialist. Right patient, right diagnosis. Dysautonomias, Endocrinology, IM, ICU, Hospice. All info is for education purposes only.

Madison, WI
Joined January 2020
Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)Photo by Jessina Graham (@PotsyNP)
Jessina Graham retweeted
There still in no approved or highly effective treatment for postural orthostatic tachycardia syndrome (POTS), which can be debilitating. Now there's hope with very encouraging results of a Phase 2 randomized trial: an antibody vs natriuretic peptide receptor 1 (NRP-1) firstwordpharma.com/story/84…
24
174
8
725
49,604
Jessina Graham retweeted
Regeneron’s Phase 2 trial in 82 POTS patients found that a single dose of baloncibart reduced standing heart rate by 11.4 bpm versus placebo and improved symptoms. The antibody blocks NPR1, with biomarkers suggesting increased blood volume. investor.regeneron.com/news-…
41
2
118
3,212
Jessina Graham retweeted
Replying to @niroshajmurugan
yes, and the issue goes way deeper, after adding biophysics to genetics. The biophysics shows us this software/cognitive layer, and once we see it, it applies to biochemical and biomechanical signaling too. Even conventional GRNs are seen in a new light too. What does evolution make? cell.com/trends/genetics/ful… link.springer.com/article/10… thoughtforms.life/biophysica… imho, 1) evolution works very differently when it's dealing with an agential material as substrate 2) genes are somewhere between a hardware parts list and a prompt to be creatively interpreted by the collective intelligence of cells (as a policy for navigating anatomical morphospace) 3) a lot of what's important here is a free gift from math (not physics or selection); replication and selection is only part of the story
16
15
4
195
5,492
Jessina Graham retweeted
Help!!!! Any advice appreciated!!! We just lost our strong lead in the HHS TOPx voting and I want to get the word out about what we're trying to do and what a difference it makes to get objective measures! Any tips appreciated (also votes and comments)!!! invisibleillness.crowdicity.…
6
16
2
29
5,285
Lactoferrin is such an interesting molecule. The dosing is all across the board in studies, but it’s interesting to me across multiple diseases and mechanisms. Study linked below: pmc.ncbi.nlm.nih.gov/article…
1
2
114
Jessina Graham retweeted
EPO injections improved 71% of treatment refractory POTS pts for 6 mos duration of open label study. Also improved diastolic BP. Why hasn't this been studied at scale in blinded RCT? If 13% volume depletion in POTS w "nl" HCT -> low RBC mass in many. pubmed.ncbi.nlm.nih.gov/2083…
5
11
2
37
3,173
Why is IVIG covered under Medicare Part B for one home infusion diagnosis, but Part D under a different set of home infusion diagnoses? I ask bc you can make a medical necessity argument for Part B. Much harder for part D denials. Very frustrating, as an advocate.
2
96
Hot take: We neurologists probably don’t biopsy enough for Sjögren’s disease. SSA/SSB antibodies have imperfect sensitivity, and we’re increasingly recognizing the breadth of neurologic manifestations. Sjögren’s is also increasingly recognized as a cause of non-length-dependent small-fiber neuropathy, which is always in my head when a patient presents with facial numbness. A minor salivary gland biopsy showing focal lymphocytic sialadenitis and other supportive features can be really helpful in giving patients an explanation for symptoms that may have otherwise been difficult to contextualize. And maybe, in some cases, helping them feel a little less dismissed.
13
31
3
190
25,106
In light of the new guidelines on ferritin, I've written about iron dysregulation in #endometriosis, and some of the trends we're seeing in research. Article linked below:
1
1
8
1,144
ADHD meds target dopamine, but iron is required to make it. Research links low ferritin with ADHD severity, lower brain iron in some medication-naive kids, and higher amphetamine dose needs in one study. grahammedical.substack.com/p…
97
A few days ago, I learned that @NatGeo quoted two (!) of my studies on autoimmunity and immunotherapies in #POTS and #LongCOVID in their recent article. I am honored! The study on autoimmunity in POTS is from over 10 years ago, but is clearly impactful. nationalgeographic.com/healt…
13
57
2
362
10,365
Autism and schizophrenia genes are considered older than depression. What are the downstream consequences of continued/complex inputs on the regulatory machine underneath our developments? Were HTN/kidney disease/DM just easier endpoints to measure than autonomic function?
1
2
179
Study link below: What interests me is the idea of how our body handled the increasing complexity, and what decades of pollutants and speedy changes in our environments asked of our systems. sciencealert.com/study-trace…
1
46
There’s risk of attrition bias when specialists report success rates without tracking patients lost to follow-up. We don’t know if they failed treatment, stopped because of adverse effects, or improved with alternative approaches. They shouldn’t disappear from the denominator.
1
4
116
Also probably a significant portion of issues in reproducing antibody responses. Not all cause, but if you don’t understand function under different conditions you may fail to reproduce results.
For the autoantibody aficionados out there, here’s a problem I’ve been thinking about a lot recently: Typically, any antibody that binds a self-antigen is considered an “autoantibody.” But when you examine reactivity patterns, an important distinction emerges between antibodies that bind predominantly to a single antigen (e.g., anti-TSHR antibodies in Graves’ disease) and promiscuous antibodies with highly polyreactive features. I spend most of my time thinking about the former. These are functional antibodies with specific biological effects, and I consider them a lens for discovering causal biology in humans. These are the types of responses we hoped to find when we developed REAP. I also suspect this is what most people intuitively mean when they use the term “autoantibody.” It’s unclear to me that the latter should be considered autoantibodies at all. They aren’t exclusively autoreactive: these antibodies often bind multiple unrelated self-antigens as well as microbial or viral molecular patterns. Their promiscuity is likely an evolved functional feature, rather than an immunological accident. They frequently become prominent during inflammation and can arise through extrafollicular B cell responses with reduced dependence on cognate T cell help. IGHV4-34–encoded responses exemplify this biology. These antibodies are associated with autoimmune disease and can clearly drive pathology, as in SLE, but their effects are often difficult to attribute to a single antigen–antibody interaction. I believe we should NOT call responses like these “autoantibodies” at all. We should call them what they are: polyreactive antibodies. The problem with calling both groups “autoantibodies” is that it conflates two entirely different phenomena. These antibody classes can have different origins, physiological effects, and therapeutic implications. Understanding the nature of the antibody responses likely will have a major impact whether we should pursue total immune reset vs precision antigen-specific immunomodulation vs IGHV4-34-directed targeting. Distinguishing antigen-specific autoantibodies from polyreactive responses is also critical because investigators sometimes infer specificity for an individual antigen when they are actually studying a broader polyreactive response. They may then attribute the effects of polyreactive antibodies to antigen-specific biology, which is a serious mechanistic error. This becomes particularly problematic when human antibodies are transferred into nonhuman preclinical models. For example, an increasingly popular approach involves injecting human IgG into mice. Polyreactive antibodies are known to be strongly xenoreactive, but the sets of human and mouse antigens they recognize might not overlap. That can make downstream effects extremely difficult to interpret, even before considering differences in Fc biology, pharmacokinetics, and the immunogenicity of human IgG in mice. I clearly have a dim view of this approach. Distinguishing monospecific from polyreactive responses in seromic data from patient samples can be very difficult, especially when both types of reactivity are present. However, we are having increasing success with new metrics (tentatively including a “promiscuity index”) that identify patterns of inter-antigen reactivity correlation that recur across patients in a dataset. These metrics do not prove polyreactivity, but they can flag signals that may be better characterized as polyreactive rather than specifically autoreactive and (de)prioritize them for experimental validation. I’m also hopeful that it may be possible to selectively deplete polyreactive antibodies from samples before specificity analysis, allowing seromic signals to be attributed more confidently to specific autoreactivity rather than polyreactivity. Anyway, if you got this far, thank you for reading and please add your thoughts below.
3
275
📢 A new small study from Germany involving 18 patients with #POTS + hEDS and 20 healthy controls, utilizing MRI of the middle cerebral artery (MCA) and lower-body negative pressure chamber showed that patients with POTS/hEDS experience significant decrease in MCA flow when negative low-body pressure is applied, leading to increased heart rate and breathing rate and decreased end-tidal CO2 compared to healthy controls. ❓ What does that mean? As other researchers have shown in the past and, as is confirmed by this new study, there is altered physiology in patients with POTS that is associated with reduced blood flow to the brain - aka cerebral hypoperfusion. 💡 One hypothesis that can be generated from this study is that heart rate and breathing rate increase disproportionally in patients with POTS/hEDS to preserve adequate blood flow to the brain. 🧠 What else does it mean? Many things! 😃 1⃣ Heart rate elevation and increased respiration rate are INVOLUNTARY and occur in response to pathophysiologic factors. 2⃣ You cannot change your heart rate and respiration rate with positive thinking and the "right attitude": heart rate and respiration are controlled by the brainstem and not the cortex where thought process lives - i.e. POTS is not anxiety, depression, fear, FND, etc. 3⃣ Compensatory attempt by the body to preserve blood flow to the brain is vastly different from healthy blood flow to the brain ➡️ Expect brain changes on a cellular level, which in turn result in brain symptoms experienced by the patients. 4⃣ This MRI finding of reduced MCA blood flow in patients with POTS/hEDS may be an objective biomarker of disease process if replicated in large studies➡️ Anyone who says "we don't have biomarkers" is not following the literature. 5⃣ We don't know what the CAUSE of this altered physiology is as there are likely many of these CAUSES, which all lead down the same path of cerebral hypoperfusion and neuroinflammation. 6⃣ I am very interested in THERAPEUTIC TRIALS targeting cerebral hypoperfusion, neuroinflammation and neuroimmune etiology. This is where we SHOULD be investing our resources and our funding!!! ahajournals.org/doi/10.1161/…
12
116
9
403
11,006
One large roadblock to systems medicine isn’t even the isolated specialties. It’s that the fields have different languages. And it gets even more complex as you move across species. Terms change too. One receptor can change names multiple times, even within the same field.
4
166